https://agi1067.com/covid-19-o....ver-the-face-of-your
Luckily , our knowledge of some great benefits of glucose-lowering agents from the sodium-glucose co-transporter-2 (SGLT2) inhibitor and glucagon-like peptide-1 (GLP-1) receptor agonist courses on aerobic and kidney effects is advancing; this implies we now have brand-new choices to mitigate the risks of these problems in patients with T2D. The SGLT2 inhibitors have consistently shown advantages on atherosclerotic heart disease (ASCVD), chronic kidney disease (CKD) and heart failure (HF) eve
Like
Comment
Share
